What are the precautions for Avonib?

Ivosidenib is an antineoplastic drug indicated for the treatment of newly diagnosed acute myeloid leukemia(AML), which has been approved by the FDA in patients aged ≥ Susceptible isocitrate dehydrogenase-1 (IDH1)mutations have been detected in adult patients 75 years of age or with comorbidities that preclude the use of intensive induction chemotherapy. Ivonib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptibility to isocitrate dehydrogenase (IDH1) mutations as determined by an FDA-approved test. What are the precautions for Avonib?

QTcinterval prolongation may occur during taking, monitor electrocardiogram and electrolytes. If QTc interval prolongation occurs, reduce or discontinue dosing and then resume dosing or permanently discontinue ivosidenib. More frequent monitoring may be needed in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or who are taking drugs known to prolong the QTc interval.

If QTc increases to greater than 480 milliseconds less than 500 milliseconds, interrupt TIBSOVO. If QTcincreases beyond 500 milliseconds, interrupt and reduce ivonib. Ivonib should be permanently discontinued in patients who develop QTc prolongation with signs or symptoms of life-threatening arrhythmias.

In one clinical study, the incidence of Guillain-Barre syndrome was less than 1% (2/258) in patients treated with ivonib. Monitor patients taking ivosidenib for new signs or symptoms of motor or sensory neuropathy, such as unilateral or bilateral weakness, altered sensation, paresthesia, or dyspnea, and patients diagnosed with Guillain-Barré syndrome should permanently discontinue ivosidenib. If you want to get more high-quality information, you can contact YaoDe,Yaode will do its best to learn more about high-quality overseas drugs for you.